Saturday 17 October 2026
Export RNTX’s income statement to Excel — free account
Rein Therapeutics Inc.
RNTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 64.3% and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.59
0.04
−6.35%
Follow RNTX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | 175.40 | 10.40 | 8.00 | 5.00 | 10.20 | 1.79 | 1.01 | 1.61 | 1.02 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | 309.60 | 220.00 | 52.00 | 49.40 | 46.60 | 15.00 | 5.49 | 7.42 | 3.50 | |||||
| People | |||||||||||||||
| People | Employees | 15 | 13 | 23 | 13 | 8 | 9 | 6 | 15 | 11 | 10 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (18) | (23) | (32) | (29) | (21) | (26) | (27) | (16) | (64) | (51) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (18) | (23) | (32) | (29) | (21) | (26) | (27) | (16) | (63) | (50) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37 | 29 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (842.93) | (60.80) | (42.80) | (24.00) | (12.20) | (5.80) | (6.02) | (3.42) | (3.51) | (1.96) | |||||
| Cash flow | (698.33) | (55.16) | (37.90) | (21.58) | (11.74) | (5.35) | (5.48) | (4.31) | (1.24) | (0.76) | |||||
| Capex | 0.00 | (0.38) | (6.00) | (0.12) | 0.12 | (0.02) | 0.00 | 0.01 | 0.00 | 0.00 | |||||
| Free cash flow | (698.33) | (55.54) | (43.90) | (21.70) | (11.63) | (5.37) | (5.48) | (4.30) | (1.24) | (0.76) | |||||
| Book value | (5,200.28) | 128.42 | 26.60 | 13.08 | 6.98 | 9.89 | 4.10 | 1.50 | 0.52 | (1.10) | |||||
| Shares, m | 0 | 0 | 1 | 1 | 2 | 4 | 5 | 5 | 18 | 25 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (15) | (21) | (28) | (26) | (20) | (24) | (25) | (20) | (22) | (19) | ||||
| Capex | — | 0 | (4) | 0 | 0 | 0 | — | 0 | — | — | |||||
| Free cash flow | (15) | (21) | (32) | (27) | (20) | (24) | (25) | (20) | (22) | (19) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 17 | 47 | 16 | 14 | 12 | 44 | 18 | 14 | 8 | (2) | ||||
| Total debt | — | — | 5 | 5 | 0 | 0 | 0 | — | — | — | |||||
| Net debt | (21) | (51) | (15) | (13) | (14) | (46) | (21) | (17) | (13) | (3) | |||||
| Shareholders’ equity | (112) | 48 | 20 | 16 | 12 | 44 | 19 | 7 | 9 | (28) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (165.28) | (60.62) | (76.02) | (103.44) | (98.83) | (80.73) | (77.54) | (24.58) | (74.77) | (115.51) | ||||
| ROIC | 0.00 | 0.00 | (472.26) | (674.20) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | 56.86 | 70.76 | (93.62) | (164.77) | (150.00) | (93.33) | (87.42) | (123.34) | (772.80) | 533.38 | |||||
Negative figures in brackets.
Charts ten years each
Rein Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TENX Tenax Therapeutics, Inc. | $56.5M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALPS Alps Group Inc. | $56.4M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $55.3M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GUTS Fractyl Health, Inc. | $55.2M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GOSS Gossamer Bio, Inc. | $54.3M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| RNTX Rein Therapeutics Inc. | $54.2M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +115.40% (above 0%: growing) | n/m | −27.63% (below 0%: shrinking) | 84.27% | (368.43%) | Compare |
| BOLD Boundless Bio, Inc. | $53.5M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | Compare |
| ATHE Alterity Therapeutics Limited - Sponsored ADR | $52.0M | — (loss-making) | — | — | 0.00% | −84.83% (below 0%: shrinking) | 0.00% | — | Compare |
| Median of peers | $54.8M | — | — | −38.36% | — | −52.27% | 92.14% | 0.00% |
Rein Therapeutics Inc. (RNTX) key facts
- Rein Therapeutics Inc. (RNTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, RNTX traded at $0.59, a market capitalization of $54.2 million.
- Return on equity was 533.4% and debt-to-equity 0.00.